289 related articles for article (PubMed ID: 19696041)
21. New options with dabigatran etexilate in anticoagulant therapy.
Maegdefessel L; Spin JM; Azuma J; Tsao PS
Vasc Health Risk Manag; 2010 May; 6():339-49. PubMed ID: 20531953
[TBL] [Abstract][Full Text] [Related]
22. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
[TBL] [Abstract][Full Text] [Related]
23. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
[TBL] [Abstract][Full Text] [Related]
24. Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Wilcox R; Pendleton RC; Smock KJ; Rodgers GM
Hosp Pract (1995); 2011 Aug; 39(3):23-34. PubMed ID: 21881389
[TBL] [Abstract][Full Text] [Related]
25. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
26. Implications of new anticoagulants in primary practice.
Perez A; Eraso LH; Merli GJ
Int J Clin Pract; 2013 Feb; 67(2):139-56. PubMed ID: 23305476
[TBL] [Abstract][Full Text] [Related]
27. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
Bovio JA; Smith SM; Gums JG
Ann Pharmacother; 2011 May; 45(5):603-14. PubMed ID: 21540406
[TBL] [Abstract][Full Text] [Related]
28. Pooled analysis of trials may, in the presence of heterogeneity inadvertently lead to fragile conclusions due to the importance of clinically relevant variables being either hidden or lost when the findings are pooled.
Hull RD; Liang J; Brant R
Thromb Res; 2010 Sep; 126(3):164-5. PubMed ID: 20542545
[No Abstract] [Full Text] [Related]
29. Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo.
Fuji T; Fuijita S; Ujihira T; Sato T
J Arthroplasty; 2010 Dec; 25(8):1267-74. PubMed ID: 19854610
[TBL] [Abstract][Full Text] [Related]
30. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
Eriksson BI; Dahl OE; Büller HR; Hettiarachchi R; Rosencher N; Bravo ML; Ahnfelt L; Piovella F; Stangier J; Kälebo P; Reilly P;
J Thromb Haemost; 2005 Jan; 3(1):103-11. PubMed ID: 15634273
[TBL] [Abstract][Full Text] [Related]
31. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
[TBL] [Abstract][Full Text] [Related]
32. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
Wolowacz SE; Roskell NS; Plumb JM; Clemens A; Noack H; Robinson PA; Dolan G; Brenkel IJ
Thromb Haemost; 2010 Feb; 103(2):360-71. PubMed ID: 20024501
[TBL] [Abstract][Full Text] [Related]
34. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
Eriksson BI; Dahl OE; Ahnfelt L; Kälebo P; Stangier J; Nehmiz G; Hermansson K; Kohlbrenner V
J Thromb Haemost; 2004 Sep; 2(9):1573-80. PubMed ID: 15333033
[TBL] [Abstract][Full Text] [Related]
35. Dabigatran etexilate in venous thromboembolism.
Ferrer E
Drugs Today (Barc); 2009 Oct; 45(10):715-24. PubMed ID: 20069135
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
[TBL] [Abstract][Full Text] [Related]
37. Practical use of apixaban in the prevention of venous thromboembolism after total knee or hip replacement.
Lassen MR
Drugs Today (Barc); 2012 Apr; 48(4):249-58. PubMed ID: 22536567
[TBL] [Abstract][Full Text] [Related]
38. Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.
Friedman RJ; Kurth A; Clemens A; Noack H; Eriksson BI; Caprini JA
Thromb Haemost; 2012 Jul; 108(1):183-90. PubMed ID: 22552763
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.
Postma MJ; Kappelhoff BS; van Hulst M; Brouwers JR
J Med Econ; 2012; 15(5):878-86. PubMed ID: 22563715
[TBL] [Abstract][Full Text] [Related]
40. Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients.
Ageno W; Spyropoulos AC; Turpie AG
Thromb Haemost; 2012 Jun; 107(6):1027-34. PubMed ID: 22437976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
